Razoxane and Dexrazoxane - Two Multifunctional Agents [recurso electrónico] : Experimental and Clinical Results / edited by Kurt Hellmann, Walter Rhomberg.
Tipo de material:
TextoEditor: Dordrecht : Springer Netherlands : Imprint: Springer, 2011Descripción: XIII, 243 p. online resourceTipo de contenido: text Tipo de medio: computer Tipo de portador: online resourceISBN: 9789048191680Tema(s): Medicine | Oncology | Neurosciences | Radiotherapy | Internal medicine | Cardiology | Biomedicine | Cancer Research | Oncology | Radiotherapy | Cardiology | Internal Medicine | NeurosciencesFormatos físicos adicionales: Printed edition:: Sin títuloClasificación CDD: 614.5999 Clasificación LoC:RC261-271Recursos en línea: Libro electrónico
En: Springer eBooksResumen: Razoxane and dexrazoxane are two novel drugs with some uniquely useful features. They block cell division at the G2/M border, but nowhere else, so that they have a low toxicity profile. They suppress tumor metastasis and haemorrhages through normalization of pathological blood vessels. Razoxane potentiates radiotherapy especially in the treatment of soft tissue sarcomas and gastrointestinal neoplasms. They protect normal tissues against toxic chemicals, e.g. the myocardium against anthracyclines or subcutaneous tissue against injuries caused by incidental extravasations of anthracyclines. Dexrazoxane is the only drug approved by the FDA/EMEA for the specific purpose of preventing cardiac damage when giving the widely used and effective antitumor anthracyclines. The reduction of cardiotoxicity is achieved without response reduction or reducing of time to progression of tumors. While the full analysis of their actions at the molecular level is not yet completely understood, it seems most likely that it is via an inhibition on the topoisomerase II a. Moreover, the drugs have the ability to chelate several metals including iron, copper or zinc. The protection of normal tissues is nowhere more important than that of brain, and there are indications that the proteins thought to be responsible for the ravages of Alzheimer´s disease could be stabilized by one or both these drugs.
| Tipo de ítem | Biblioteca actual | Colección | Signatura | Copia número | Estado | Fecha de vencimiento | Código de barras |
|---|---|---|---|---|---|---|---|
| Libro Electrónico | Biblioteca Electrónica | Colección de Libros Electrónicos | RC261 -271 (Browse shelf(Abre debajo)) | 1 | No para préstamo | 377933-2001 |
Navegando Biblioteca Electrónica Estantes, Código de colección: Colección de Libros Electrónicos Cerrar el navegador de estanterías (Oculta el navegador de estanterías)
| RC261 -271 Pharmacogenetics: Making cancer treatment safer and more effective | RC261 -271 Methods of Cancer Diagnosis, Therapy, and Prognosis | RC261 -271 Metastasis of Colorectal Cancer | RC261 -271 Razoxane and Dexrazoxane - Two Multifunctional Agents | RC261 -271 Circulating Nucleic Acids in Plasma and Serum | RC261 -271 Therapeutic Angiogenesis for Vascular Diseases | RC261 -271 Oncothermia: Principles and Practices |
Razoxane and dexrazoxane are two novel drugs with some uniquely useful features. They block cell division at the G2/M border, but nowhere else, so that they have a low toxicity profile. They suppress tumor metastasis and haemorrhages through normalization of pathological blood vessels. Razoxane potentiates radiotherapy especially in the treatment of soft tissue sarcomas and gastrointestinal neoplasms. They protect normal tissues against toxic chemicals, e.g. the myocardium against anthracyclines or subcutaneous tissue against injuries caused by incidental extravasations of anthracyclines. Dexrazoxane is the only drug approved by the FDA/EMEA for the specific purpose of preventing cardiac damage when giving the widely used and effective antitumor anthracyclines. The reduction of cardiotoxicity is achieved without response reduction or reducing of time to progression of tumors. While the full analysis of their actions at the molecular level is not yet completely understood, it seems most likely that it is via an inhibition on the topoisomerase II a. Moreover, the drugs have the ability to chelate several metals including iron, copper or zinc. The protection of normal tissues is nowhere more important than that of brain, and there are indications that the proteins thought to be responsible for the ravages of Alzheimer´s disease could be stabilized by one or both these drugs.
19
